Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
PT-141 is a synthetic cyclic heptapeptide developed in the late 1990s and early 2000s as a melanocortin receptor agonist for research applications in central nervous system signaling. The compound emerged from medicinal chemistry programs investigating melanocortin pharmacology and is structurally derived from alpha-melanocyte-stimulating hormone (α-MSH) through a series of modifications designed to enhance receptor selectivity and metabolic stability. PT-141 research has produced one of the more mechanistically detailed accounts of melanocortin-mediated central signaling in rodent preclinical models.
The peptide is a non-selective melanocortin receptor agonist with reported activity at MC1R, MC3R, MC4R, and MC5R. Among these, its activity at the centrally expressed MC4 receptor has received the most sustained mechanistic attention, as MC4R signaling in hypothalamic circuits is implicated in a wide range of behaviors including reproductive, ingestive, and autonomic outputs.
This article reviews the published preclinical record on PT-141, the molecular pharmacology of melanocortin receptor agonism, and the laboratory considerations relevant to investigators working with the compound. The mechanistic and behavioral literature on PT-141 spans nearly twenty-five years and has been developed by multiple independent groups, providing a relatively mature foundation for new research investigations.
Molecular Profile
PT-141 is a cyclic heptapeptide containing seven amino acid residues organized in a constrained ring structure that includes both natural and modified amino acids. The compound has a molecular formula of C₅₀H₆₈N₁₄O₁₀ and a molecular weight of approximately 1,025.18 Da. The cyclic architecture confers metabolic stability and constrains the peptide conformation in a manner favorable for melanocortin receptor binding.
The peptide is water-soluble and is supplied as a lyophilized white powder produced by solid-phase peptide synthesis followed by cyclization. The structural design — building on the conserved His-Phe-Arg-Trp (HFRW) melanocortin pharmacophore at the core of the molecule — reflects extensive medicinal-chemistry work on melanocortin receptor selectivity that was conducted across multiple laboratories in the 1990s.
The His-Phe-Arg-Trp pharmacophore is a defining motif of the melanocortin family, present in α-MSH and shared across natural and synthetic ligands that engage melanocortin receptors. The cyclic constraint in PT-141 stabilizes the bioactive conformation of this motif and protects the peptide from proteolytic cleavage by aminopeptidases that would otherwise degrade a linear analog. The result is a research peptide with improved pharmacokinetic stability relative to natural α-MSH while retaining the core receptor-binding pharmacology of the parent hormone. These chemistry choices make PT-141 a useful tool for studies that require sustained melanocortin receptor engagement, particularly in behavioral paradigms with time courses longer than the rapid-clearance window of unmodified α-MSH.
Mechanism of Action
PT-141 binds as an agonist to multiple members of the melanocortin receptor family. The melanocortin receptors are seven-transmembrane G-protein-coupled receptors that signal predominantly through Gαs and adenylyl cyclase, leading to elevated intracellular cAMP and downstream PKA activation. The receptor family includes MC1R (pigmentation), MC2R (adrenal), MC3R and MC4R (central — hypothalamic), and MC5R (peripheral exocrine).
The mechanism of PT-141’s reported behavioral effects in rodent models centers on central MC4R signaling. Van der Ploeg L.H.T., Martin W.J., Howard A.D., et al. published in Proceedings of the National Academy of Sciences (2002) describing a role for MC4R in centrally regulated reproductive function in male rats. Building on this framework, Pfaus J.G., Shadiack A., Van Soest T., Tse M., Molinoff P. published in Proceedings of the National Academy of Sciences (2004) reporting that PT-141 selectively facilitated solicitational behaviors in female rats following central administration, without affecting generalized motor activity or non-target behaviors.
These investigations established PT-141 as a useful pharmacological tool for dissecting central melanocortin contributions to behavioral outputs in preclinical models.
Downstream of receptor binding, MC4R activation in hypothalamic and brainstem neurons produces context-dependent effects on autonomic outflow, neuropeptide co-release, and connection patterns with reward and motivational circuits. PT-141’s activity at multiple melanocortin receptor subtypes means investigators must account for potential MC3R and MC5R contributions when interpreting behavioral or physiological readouts; selective MC4R agonists and antagonists are typically deployed alongside PT-141 in mechanistic studies to dissect receptor-specific contributions. The non-selective binding profile is sometimes a methodological limitation and sometimes an advantage — for studies probing convergent melanocortin signaling across multiple receptor subtypes, a non-selective agonist is the more appropriate tool.
Key Research Areas
1. Central Melanocortin Receptor Signaling Research
The foundational pharmacology of PT-141 was developed in the context of melanocortin receptor structure-activity research. Van der Ploeg L.H.T., Martin W.J., Howard A.D., et al. (2002), publishing in PNAS, used genetic and pharmacological approaches to establish a role for MC4R in centrally regulated reproductive function in male rats. Subsequent receptor pharmacology and binding studies have characterized PT-141’s affinity profile across the melanocortin receptor family and established its position as a non-selective melanocortin agonist with notable central activity.
Hruby V.J., Wilkes B.C., Hadley M.E., et al. have published foundational structure-activity research on cyclic melanocortin analogs that informed the design of PT-141 and related compounds. The cumulative SAR literature established that constrained cyclic analogs of α-MSH retaining the His-Phe-Arg-Trp pharmacophore can produce agonists with substantially improved pharmacokinetic profiles and intact receptor activity. King S.H., Mayorov A.V., Balse-Srinivasan P., et al. (2007), in Current Topics in Medicinal Chemistry, summarized the field of melanocortin medicinal chemistry as it applied to penile erection research, providing useful context for the PT-141 reproductive-physiology literature.
2. Preclinical Sexual Behavior Research in Female Rats
The PT-141 research literature includes a well-characterized body of work in female rat models. Pfaus J.G., Shadiack A., Van Soest T., Tse M., Molinoff P. (2004), publishing in PNAS, demonstrated that systemic administration of PT-141 increased solicitational behaviors in ovariectomized, hormonally-primed female rats observed in standard sexual behavior paradigms. The compound did not produce generalized motor activation or affect non-target behaviors, suggesting selective effects on the appetitive components of female sexual behavior. The findings positioned PT-141 as a research tool for studying the central neurobiology of female sexual motivation.
Pfaus J.G., Giuliano F., and Gelez H. (2007), in the Journal of Sexual Medicine, published an integrated overview of the preclinical CNS pharmacology of PT-141 in female sexual function paradigms. The review consolidated findings across multiple behavioral models including paced mating, solicitational behavior frequency, and operant approach tasks. The behavioral selectivity reported across these paradigms — increased appetitive measures without changes in motor activity or anxiety-like behavior — has made PT-141 a comparatively well-validated tool for studying the appetitive components of female sexual behavior in rodent models.
3. Preclinical Sexual Behavior Research in Male Rats
In male rat preclinical work, central administration of PT-141 has been reported to activate hypothalamic neurons (as measured by c-Fos immunoreactivity) and to influence parameters of erectile function in standardized assays. The mechanistic framework involves MC4R signaling in hypothalamic and brainstem circuits that converge on autonomic outflow pathways. These investigations have produced detailed neuroanatomical maps of melanocortin-responsive populations relevant to male reproductive physiology.
Wessells H., Gralnek D., Dorr R., et al. (2000), publishing in Urology, conducted earlier human-subject work with an α-MSH analog that helped establish the broader melanocortin framework subsequently extended in preclinical models with PT-141. Molinoff P.B., Shadiack A.M., Earle D., Diamond L.E., and Quon C.Y. (2003), in Annals of the New York Academy of Sciences, summarized the early preclinical development of PT-141 and the receptor-pharmacology rationale for its central mechanism. These papers, together with the subsequent rat behavioral literature, provide the principal foundation for PT-141’s status as a melanocortin research tool.
4. Broader Melanocortin Receptor Research Applications
Beyond reproductive neuroscience, PT-141 has been used as a pharmacological tool in studies examining melanocortin contributions to feeding behavior, autonomic regulation, and inflammatory signaling. The peptide’s non-selective melanocortin agonist profile makes it a useful comparator in studies designed to dissect MC3R from MC4R contributions, particularly when used alongside selective antagonists at individual receptor subtypes.
For investigators studying related melanocortin research peptides with distinct receptor selectivity profiles, Melanotan-2 represents the most widely studied non-selective melanocortin agonist with reported activity at MC1R, MC3R, MC4R, and MC5R, and provides a useful comparator in mechanistic studies. Shadiack A.M., Sharma S.D., Earle D.C., et al. (2007) provided a comprehensive review of melanocortin pharmacology in sexual function research that contextualizes PT-141 within this broader landscape.
Comparative Research Landscape
PT-141 occupies a distinctive position in melanocortin research peptide pharmacology, and several comparators help clarify what the peptide does and does not offer as a research tool.
Within the broader melanocortin family, α-MSH itself is the natural full agonist at MC1, MC3, MC4, and MC5 receptors but suffers from rapid proteolytic clearance, limiting its utility in in vivo studies. Melanotan-1 (a linear α-MSH analog) and Melanotan-2 (a cyclic analog with improved selectivity) are the most commonly cited synthetic non-selective melanocortin agonists alongside PT-141. Melanotan-2 has the most extensive preclinical literature on pigmentation and feeding behavior, while PT-141 has the most developed published record in reproductive behavior paradigms. The three compounds — α-MSH, Melanotan-2, and PT-141 — are sometimes used in parallel in receptor pharmacology studies as a way of cross-validating effects across compounds with overlapping but distinct binding profiles.
Subtype-selective melanocortin tools — including the MC4R-selective agonist THIQ, the MC3R-selective agonist NDP-α-MSH analogs, and the MC4R-selective antagonist HS024 — provide essential complements to PT-141 in mechanistic studies. The non-selective profile of PT-141 means that subtype-selective comparators are typically required to attribute observed effects to specific melanocortin receptor subtypes. Pairing PT-141 with selective antagonists (e.g., SHU9119 for MC3/4R, HS014 for MC4R) is a standard approach in published rodent behavioral and pharmacological studies.
For investigators interested in linking melanocortin pharmacology to other hypothalamic peptide systems, PT-141 provides a useful tool for studies examining cross-talk between melanocortin signaling and ingestive, autonomic, or reproductive circuits. The cumulative literature now provides a relatively granular account of PT-141’s neuroanatomical and behavioral effects in standard rodent paradigms, giving the peptide a comparatively strong foundation as a research reagent.
Research Considerations for Laboratory Use
For investigators working with PT-141 in laboratory settings, the peptide’s high aqueous solubility and well-characterized molecular profile simplify handling. Lyophilized material should be stored at −20°C or below prior to reconstitution. Reconstituted solutions are typically prepared in sterile bacteriostatic water or 0.9% saline. The compound does not require DMSO or other organic carrier solvents for aqueous preparation, and reconstituted material should be used promptly or stored short-term at 2–8°C consistent with stability data for the preparation.
Research-grade PT-141 is typically characterized at ≥98% purity by HPLC analysis, with identity confirmed by mass spectrometry (expected molecular weight: 1,025.18 Da). The cyclic architecture of the molecule should be verified through mass spectrometric analysis to confirm correct cyclization. Lot-specific certificates of analysis (CoAs) documenting purity, water content, residual solvents, and sterility are standard practice for research procurement. Research-grade PT-141 (bremelanotide) supplied for laboratory use should be accompanied by this lot-specific documentation.
Research Methodology Considerations
Designing rigorous PT-141 experiments requires careful attention to several methodology considerations that arise from the peptide’s cyclic architecture, non-selective melanocortin agonism, and central nervous system mechanism of action.
Assay Selection and Readouts
The most commonly reported in vitro readouts in PT-141 mechanistic work are cAMP accumulation assays in cells stably expressing individual melanocortin receptor subtypes (typically HEK293 or CHO cell lines), competition binding assays with radiolabeled α-MSH analogs, and reporter-gene assays for downstream signaling. In vivo readouts depend on the experimental question and include behavioral paradigms (paced mating, solicitational behavior, lordosis quotient for female rats; intromission and ejaculation latencies for male rats), neuroanatomical mapping (c-Fos immunoreactivity, microdialysis), and physiological endpoints (intracavernous pressure measurements, autonomic outflow recordings).
Animal Models
Rat models dominate the in vivo PT-141 literature, with both Sprague-Dawley and Long-Evans strains commonly used in behavioral paradigms. Mouse models have been used to a lesser extent, including melanocortin-receptor-knockout strains for genetic dissection of receptor contributions. Cross-species comparisons should account for differences in melanocortin receptor expression patterns and behavioral repertoires; behavioral paradigms used in rats may not have direct mouse equivalents, and species differences in receptor pharmacology have been reported for some melanocortin compounds.
Dose-Ranging and Pharmacokinetics
Reported in vivo doses in rodent work span a range that depends on route of administration. Central (intracerebroventricular) dosing typically uses microgram quantities, while systemic (subcutaneous or intraperitoneal) dosing uses higher doses to account for blood-brain barrier penetration. The cyclic architecture confers improved metabolic stability relative to linear α-MSH analogs, but the peptide nonetheless has a finite plasma half-life. Investigators planning chronic-dosing studies should consider repeated administration schedules informed by the published pharmacokinetic literature.
Common Pitfalls
Several methodological pitfalls deserve attention in PT-141 work. First, the peptide’s non-selective melanocortin agonism means that observed effects can reflect contributions from multiple receptor subtypes; attributing effects to a specific subtype requires complementary genetic or pharmacological approaches. Second, behavioral studies are particularly sensitive to handling, housing, and circadian factors that can confound interpretation of melanocortin-modulated paradigms; standardization of these conditions is essential. Third, the cyclic architecture must be verified by mass spectrometry — degradation products from ring-opening can have altered receptor pharmacology.
Characterization Standards
Beyond ≥98% HPLC purity, rigorous PT-141 work calls for high-resolution mass spectrometry to confirm molecular weight and the cyclic architecture, NMR or specialized chromatographic methods to confirm structural integrity, and amino acid analysis to confirm composition. Lot-specific endotoxin testing is advisable for in vivo studies and for any in vitro work involving immune-relevant readouts. Water content by Karl Fischer titration supports accurate concentration calculations from lyophilized stock.
Controls and Comparators
Useful control conditions include vehicle-only, a melanocortin-inactive cyclic peptide of comparable size, and side-by-side dosing with subtype-selective melanocortin agonists or antagonists. For behavioral studies, an unrelated psychoactive peptide control (with comparable pharmacokinetic properties but distinct receptor pharmacology) can help distinguish melanocortin-specific from non-specific behavioral effects. Genetic models (e.g., MC4R-knockout mice) provide the most definitive way to attribute observed effects to a specific receptor subtype.
Conclusion
PT-141 occupies a useful position in melanocortin receptor research: a synthetic cyclic heptapeptide with well-characterized melanocortin agonist activity, a published body of preclinical behavioral data in rat models, and an established role as a pharmacological tool for dissecting central MC4R signaling. The preclinical literature spanning male and female rat reproductive behavior, central melanocortin neuroanatomy, and receptor pharmacology provides a substantial foundation for further mechanistic investigation.
For investigators considering PT-141 as a research reagent, the published mechanistic record provides a strong foundation for hypothesis-driven experimentation in central melanocortin biology. As with any peptide at the preclinical research stage, conclusions about clinical relevance in human systems must be drawn cautiously from preclinical data, and experimental designs should incorporate appropriate controls and validated endpoints. The combination of a constrained cyclic architecture, well-documented behavioral effects in standard rodent paradigms, and a developed comparator literature makes PT-141 one of the more useful research peptides in contemporary melanocortin neuroscience.
Frequently Asked Questions
What is PT-141?
PT-141 is a synthetic cyclic heptapeptide melanocortin receptor agonist developed in the late 1990s and early 2000s as a research tool for studying central melanocortin signaling. It is structurally derived from alpha-melanocyte-stimulating hormone (α-MSH) and binds as an agonist to multiple melanocortin receptor subtypes, with particular research interest focused on its activity at the centrally expressed MC4 receptor. It is produced for research purposes only and is not approved for human or veterinary use.
What research has been conducted on PT-141?
The PT-141 research literature spans melanocortin receptor pharmacology and binding, preclinical sexual behavior studies in male and female rats, central neuroanatomical mapping of melanocortin-responsive populations, and broader mechanistic work in autonomic and behavioral neuroscience. Foundational studies include Van der Ploeg et al. (2002) in PNAS and Pfaus et al. (2004) in PNAS.
How is PT-141 used in research settings?
In published preclinical studies, PT-141 has been administered via subcutaneous, intraperitoneal, intranasal, and central (intracerebroventricular) routes in rodent models depending on the experimental question. Investigators should consult primary literature for model-specific parameters and obtain material with verified identity and purity documentation.
What is the purity standard for research-grade PT-141?
Research-grade PT-141 is typically characterized at ≥98% purity by HPLC analysis, with identity confirmed by mass spectrometry (expected molecular weight: 1,025.18 Da). Verification of the cyclic architecture is essential. Reputable suppliers provide lot-specific certificates of analysis (CoAs) documenting purity, water content, residual solvents, and sterility — standard requirements for reproducible research protocols using synthetic peptides.
Which melanocortin receptors does PT-141 engage in published research?
PT-141 is a non-selective melanocortin receptor agonist with reported activity at MC1R, MC3R, MC4R, and MC5R. Among these, its activity at the centrally expressed MC4 receptor has received the most sustained mechanistic attention. The non-selective binding profile means that investigators interested in attributing observed effects to a specific receptor subtype typically deploy PT-141 alongside selective antagonists or in receptor-knockout models.
What is the role of the His-Phe-Arg-Trp pharmacophore in melanocortin pharmacology?
The His-Phe-Arg-Trp (HFRW) motif is the defining pharmacophore of the melanocortin receptor family, present in α-MSH and shared across natural and synthetic melanocortin ligands. The cyclic architecture of PT-141 stabilizes the bioactive conformation of this motif and protects the peptide from proteolytic degradation, resulting in improved pharmacokinetic stability relative to linear α-MSH analogs while preserving the core receptor-binding pharmacology.
How does PT-141 compare to Melanotan-2 in research applications?
Both PT-141 and Melanotan-2 are cyclic non-selective melanocortin receptor agonists derived from α-MSH structure-activity research. Melanotan-2 has the more extensive preclinical literature on pigmentation and feeding behavior, while PT-141 has the more developed published record in reproductive behavior paradigms. The two compounds are sometimes used in parallel as a way of cross-validating effects across structurally distinct but pharmacologically related melanocortin agonists.
What animal models have most commonly been used in PT-141 research?
Rat models dominate the in vivo PT-141 literature, with both Sprague-Dawley and Long-Evans strains commonly used in behavioral paradigms. Ovariectomized, hormonally-primed female rats are a standard model for solicitational behavior studies; male rats are used in intromission and ejaculation latency paradigms. Mouse models have been used to a lesser extent, including melanocortin-receptor-knockout strains for genetic dissection of receptor contributions.
Why is PT-141 considered a useful tool for central melanocortin research?
PT-141’s cyclic architecture confers metabolic stability sufficient for in vivo behavioral studies, while its melanocortin receptor pharmacology retains the activity of the parent α-MSH. The compound has been shown to penetrate the blood-brain barrier sufficiently to produce centrally mediated behavioral effects from systemic administration, making it a practical tool for studies of central melanocortin signaling that do not require central catheterization for delivery.
What endpoints are most commonly measured in PT-141 behavioral studies?
In female rat paradigms, common endpoints include solicitational behavior frequency, paced mating measures, and lordosis quotient. In male rat paradigms, intromission and ejaculation latencies are standard endpoints. Neuroanatomical endpoints include c-Fos immunoreactivity in hypothalamic and brainstem nuclei, microdialysis measures of neurotransmitter release, and electrophysiological recordings of melanocortin-responsive neurons. Physiological endpoints include intracavernous pressure measurements in erectile-function studies.
References
- Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences. 2004;101(27):10201–10204. PMID: 15226502.
- Van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proceedings of the National Academy of Sciences. 2002;99(17):11381–11386. PMID: 12172010.
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96–102. PMID: 12851303.
- King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry. 2007;7(11):1098–1106. PMID: 17584130.
- Pfaus JG, Giuliano F, Gelez H. PT-141: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine. 2007;4(Suppl 4):269–279. PMID: 17958624.
- Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641–646. PMID: 11018622.
- Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry. 2007;7(11):1137–1144. PMID: 17584134.
- Hruby VJ, Cai M, Cain JP, Mayorov AV, Dedek MM, Trivedi D. Design, synthesis, and biological evaluation of ligands selective for the melanocortin-3 receptor. Current Topics in Medicinal Chemistry. 2007;7(11):1107–1119. PMID: 17584131.
- Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by a non-hormonal melanocortin receptor agonist. Journal of Sexual Medicine. 2006;3(4):628–638. PMID: 16839319.
- Rossi J, Balthasar N, Olson D, Scott M, Berglund E, Lee CE, Choi MJ, Lauzon D, Lowell BB, Elmquist JK. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metabolism. 2011;13(2):195–204. PMID: 21284986.
PT-141 is supplied for in vitro and in vivo laboratory research use only. It is not approved for human or veterinary use.
